-
EP4219470
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4219470
| EP4219470 - JAK1 SELECTIVE INHIBITORS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 09.02.2024 Database last updated on 14.11.2024 | |
| Former | The application has been published Status updated on 30.06.2023 | Most recent event Tooltip | 09.02.2024 | The date on which the examining division becomes responsible, has been established | 09.02.2024 | Change: Validation states | published on 13.03.2024 [2024/11] | 09.02.2024 | Request for examination filed | published on 13.03.2024 [2024/11] | 09.02.2024 | Change - designated states | published on 13.03.2024 [2024/11] | 09.02.2024 | Change - extension states | published on 13.03.2024 [2024/11] | Applicant(s) | For all designated states Astrazeneca AB 151 85 Södertälje / SE | [2023/31] | Inventor(s) | 01 /
NILSSON, Karl Magnus 431 83 Mölndal / SE | 02 /
ÅSTRAND, Annika Birgitta Margareta 431 83 Mölndal / SE | 03 /
BERGGREN, Anna Ingrid Kristina 431 83 Mölndal / SE | 04 /
JOHANSSON, Johan R 431 83 Mölndal / SE | 05 /
LEPISTÖ, Matti Juhani 431 83 Mölndal / SE | 06 /
KAWATKAR, Sameer Pralhad Delaware, 19803 / US | 07 /
SU, Qibin Delaware, 19803 / US | 08 /
KETTLE, Jason Grant Cambridge, CB2 0AA / GB | [2023/31] | Representative(s) | AstraZeneca Intellectual Property Eastbrook House Shaftesbury Road Cambridge CB2 8BF / GB | [2023/31] | Application number, filing date | 22209765.1 | 16.01.2018 | [2023/31] | Priority number, date | US201762447057P | 17.01.2017 Original published format: US 201762447057 P | [2023/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4219470 | Date: | 02.08.2023 | Language: | EN | [2023/31] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 24.05.2023 | Classification | IPC: | C07D403/04, C07D403/14, A61K31/506, A61P17/14, A61P37/00 | [2023/31] | CPC: |
A61P37/00 (EP,EA,IL,KR);
C07D403/04 (EP,EA,IL,KR);
A61K9/0075 (EA,US);
C07D403/14 (EP,EA,IL,KR,US);
A61K31/506 (KR);
A61P17/14 (EP,EA,IL,KR,US);
A61P3/10 (KR)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/11] |
| Former [2023/31] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Extension states | BA | 02.02.2024 | ME | 02.02.2024 | Validation states | MA | 02.02.2024 | TN | 02.02.2024 | Title | German: | JAK1-SELEKTIVE INHIBITOREN | [2023/31] | English: | JAK1 SELECTIVE INHIBITORS | [2023/31] | French: | INHIBITEURS SÉLECTIFS DE JAK1 | [2023/31] | Examination procedure | 11.01.2024 | Amendment by applicant (claims and/or description) | 02.02.2024 | Examination requested [2024/11] | 02.02.2024 | Date on which the examining division has become responsible | Parent application(s) Tooltip | EP18701296.8 / EP3571192 | Fees paid | Renewal fee | 27.03.2023 | Renewal fee patent year 03 | 27.03.2023 | Renewal fee patent year 04 | 27.03.2023 | Renewal fee patent year 05 | 27.03.2023 | Renewal fee patent year 06 | 31.01.2024 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2009046416 (TARGEGEN INC [US], et al) | by applicant | WO2015061665 |